semaglutide

News

Novo Nordisk, Lilly highlight oral obesity drugs at ADA

New data from Novo Nordisk’s phase 3 trial of an oral, high-dose formulation of semaglutide reinforces its potential as a weight-loss therapy in obesity, but Eli Lilly is

News

Novo Nordisk says oral Wegovy hits weight loss goal

Novo Nordisk has struck back in its growing rivalry with Eli Lilly in the obesity market, with data showing a higher-dose version of its oral version of weight loss drug W

News

FDA ends 7-year obesity drug drought, clearing Novo Nordisk'...

Novo Nordisk is celebrating the FDA approval of its GLP-1 agonist semaglutide as a treatment for obesity, which it believes has the potential to redefine the market for weight-loss medicine

News

Gilead pushes on with NASH partnership with Novo Nordisk

Gilead is one of many pharmas chasing mega-bucks promised by the fatty liver disease known as NASH – but after

News

Novo Nordisk’s semaglutide effective against obesity in new ...

Novo Nordisk’s hopes of getting semaglutide approved for obesity management may have received a boost, with a new, large trial showing the drug was able to cut body weight significantly over the

News

Gilead and Novo plot next steps after trial data from NASH c...

Gilead and Novo Nordisk have announced their drug combinations for the fatty liver disease known as NASH checked out in a mid-stage proof-of-concept study.

Novo Nordisk, Lilly highlight oral obesity drugs at ADA

Novo Nordisk says oral Wegovy hits weight loss goal

FDA ends 7-year obesity drug drought, clearing Novo Nordisk'...

Gilead pushes on with NASH partnership with Novo Nordisk

Novo Nordisk’s semaglutide effective against obesity in new ...

Gilead and Novo plot next steps after trial data from NASH c...

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

semaglutide

Editor's Picks